BD Statement on FDA Circulatory System Devices Panel Regarding Paclitaxel-Coated Devices - Vascular Disease Management

BD Statement on FDA Circulatory System Devices Panel Regarding Paclitaxel-Coated Devices  Vascular Disease Management

FRANKLIN LAKES, N.J., June 20, 2019 — BD (Becton, Dickinson and Company) issued the following statement following the U.S..



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more